Aveva

Subscribed

You have successfully submitted your enquiry. Someone from our company will respond ASAP

Transdermal Drug Delivery Systems

Website
www.avevadds.com
Email Address
Address
Florida,
United States of America
Phone
+1 954 624 1374 (VP business development)
Fax Number

The ideal partner to bring your product to commercial success, offering a breadth of transdermal innovation from a depth of experience.

Aveva is a global leader in transdermal drug delivery located in the US. The company has an extensive history of providing pharmaceutical partners with fully integrated, controlled-release transdermal products that fulfill unmet market needs or supply high-quality, affordable brand equivalents. By leveraging this experience, Aveva offers a full range of research, development and manufacturing capabilities to produce transdermal pharmaceutical products that can improve the quality of life, usage and compliance rates for patients.

Aveva uses a number of sophisticated technologies to produce proprietary and generic transdermal drug delivery systems that fortify R&D pipelines and enhance compounds by:

  • Enhancing bioavailability via bypassing first pass metabolism
  • Minimizing pharmaco-kinetic peaks and troughs
  • Improving tolerability and dosing
  • Increasing patient compliance
  • Continous delivery

Commercial successes can be found in the following therapeutic categories:

Cadaver skin permeation testing helps determine the feasibility of a compound to be incorporated into a transdermal drug delivery system.
  • Smoking cessation
  • Pain management
  • Cardiovascular disease
  • Dermatologicals
  • Nutraceuticals
  • Central nervous system

Approved products:

  • Fentanyl Transdermal Patch (pain) – approved in the US and Canada in 2008
  • Clonidine Transdermal Patch (hypertension) – approved in the US August 2009
  • Clearback Nicotine Transdermal Patch (smoking cessation) – approved in the US, Canada, Korea and Colombia

Customized transdermal drug delivery systems

Our deal configurations are designed for maximum flexibility in accordance with the needs of our partners, and are as unique to each client as our customized transdermal drug delivery systems:

  • Challenge our scientists to perform feasibility studies for transdermal administration of your product using innovative techniques in computer modeling and cadaver skin permeation testing
  • Collaborate with us on R&D for new chemical entities (NCE) and accretive lifecycle management (LCM) of portfolio compounds
  • Capitalize on global opportunities for commercialization of approved products from Aveva Drug Delivery Systems

Overcoming formulation challenges with creative solutions

At Aveva Drug Delivery Systems, we don’t employ just one process in the development of transdermal drug delivery systems. We create individualized systems that are specifically designed for the chemical entity, rapidly and cost-effectively generating unique products to meet specialized needs.

We clearly recognize and understand the need for leading-edge capabilities and innovative technologies in order to open up a growing pool of new pharmaceutical compounds for transdermal drug delivery.

Press Releases

  • Aveva to Exhibit at CPhI 2011

    Aveva Drug Delivery Systems is pleased to announce that it will be exhibiting at CPhI 2011, 25-27 October 2011 in Frankfurt, Germany. Aveva is part of the Nitto Denko Group of companies, which is a pioneer and one of the world's largest manufacturers of transdermal drug delivery system

  • Aveva Drug Delivery Systems to Exhibit at CRS 2011

    Aveva Drug Delivery Systems is pleased to announce that it will be exhibiting at the 38th Annual Meeting & Exposition of the Controlled Release Society, 30 July - 3 August 2011 at National Harbor, Maryland, US. Aveva is part of the Nitto Denko Group of companies, which is a pioneer

  • Meet Aveva DDS at the 2011 BIO International Convention

    Aveva Drug Delivery Systems is pleased to announce that it will be exhibiting at the 2011 BIO International Convention, which will be held 27-30 June in Washington DC, US. Aveva is part of the Nitto Denko Group of companies, which is a pioneer and one of the world's largest manufacturer

  • Aveva to Exhibit at Drug Delivery Partnerships in Miami

    Aveva Drug Delivery Systems is pleased to announce that it will be exhibiting as a sponsor at the 15th Annual Drug Delivery Partnerships Conference and Exhibition on 26-28 January 2011 in Miami, Florida, US. Aveva is part of the Nitto Denko Group of companies, which is a pioneer and one

  • AVEVA to Exhibit at Drug Delivery Partnerships 2011

    Aveva Drug Delivery Systems is pleased to announce that it will exhibit at Drug Delivery Partnerships on 26-28 January 2011 in Miami, Florida, US. Aveva Drug Delivery Systms is part of the Nitto Denko Group of companies, which is a pioneer and one of the world's largest manufacturers of

  • Aveva Drug Delivery Systems to Exhibit at AAPS 2010

    Aveva Drug Delivery Systems is pleased to announce that it will exhibit at the 2010 AAPS Annual Meeting and Exposition taking place on 14-18 November 2010 in New Orleans, Louisiana, US. Aveva Drug Delivery Systms is part of the Nitto Denko Group of companies, which is one of the world's

  • ProStrakan Receives US FDA Approval for Sancuso

    On 15 September 2008 ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announced it has received approval from the US Food and Drug Administration (FDA) for Sancuso®, ProStrakan's novel, patent-protected transdermal patch for the prevention of chemotherapy-

  • Aveva's Partner Received FDA Approval for Onsolis

    FDA approves opioid pain reliever with required risk reduction plan. On 16 July 2009 the US Food and Drug Administration approved Onsolis, medication intended for certain patients with cancer to help manage breakthrough pain – severe flares of pain that break through regular pain medica

  • Meet Us at CPhI 2009

    Aveva Drug Delivery Systems will be exhibiting at CPhI 2009 in Madrid, Spain, 13-15 October, in booth number USP071. Contact Mrs Ivis Alonso to schedule a meeting at our booth: ivis.alonso@avevadds.com Aveva is a world leader in transdermal drug delivery with a broad array of

  • BDSI Announces Supply Agreement Relating to BEMA™ Fentanyl

    Agreement with Aveva Drug Delivery Systems a Key Milestone as BDSI Enters Phase III Trial. MORRISVILLE, N.C.--(BUSINESS WIRE)-- Nov. 8, 2005-- BioDelivery Sciences International, Inc. (NASDAQ: BDSI - News, BDSIW - News), a specialty pharmaceutical company, today announced that i

Projects

Address
Aveva Drug Delivery Systems
Florida
United States of America

Email address
Phone
+1 954 624 1374 (VP business development)
Fax Number
www.avevadds.com